ArticleBMC cancer2025
Development and validation of a diagnostic and screening method for gastric cancer by combining new gastric cancer screening score and serum biomarkers: a prospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A PET-Derived SUVmax-to-Albumin Ratio Predicts Recurrence After Neoadjuvant FLOT in Gastric Cancer.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe New Gastric Cancer Screening Score (NGCSS) has been widely applied in the screening of gastric cancer (GC). The purpose of this study is to establish a novel system for GC screening and early diagnosis by combining NGCSS with serum tumor markers and to validate its robustness.
methodsPatients with GC and non-GC diseases, including superficial gastritis (SG), atrophic gastritis (AG), and intestinal metaplasia (IM), were included in the study. They were allocated to a discovery dataset and a validation dataset in a 2:1 ratio. All individuals underwent standardized NGCSS scoring. Additionally, serum samples were obtained for tumor marker detection, including three traditional markers (CA724, CEA, and CA199) and five novel GC-related markers (OPN, TEF3, SOX3, IGFBP1, and Leptin).
resultsA total of 106 GC and 143 non-GC patients were included in this study, with 167 assigned to the discovery dataset and 82 to the validation dataset. In the discovery dataset, GC and different types of non-GC patients exhibited distinct NGCSS scores and grade levels (P < 0.01). Furthermore, compared to non-GC, GC patients showed significantly increased levels of CEA, OPN, and IGFBP1 in serum (P < 0.001). Multivariate logistic regression indicated that each marker was an independent indicator of GC incidence related to NGCSS (P < 0.001). Additionally, by selecting cutoff values for CEA, OPN, and IGFBP1, a NGCSS-CS[Changshu] screening and prediction system with a total score of 62 points was constructed. Analysis of the validation dataset revealed that NGCSS-CS had better diagnostic performance (AUC = 0.967, P < 0.001) and effectively differentiated between GC and non-GC patients (P < 0.001).
conclusionThe new model system based on NGCSS combined with multiple tumor markers is feasible and exhibits improved diagnostic performance. The conclusions of this study require further validation and elaboration through large-sample multicenter follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.